Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $344.82 Consensus Target Price from Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) has earned an average rating of "Hold" from the fourteen ratings firms that are covering the firm, Marketbeat reports. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $344.82.

A number of research analysts have weighed in on MEDP shares. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and dropped their price objective for the company from $370.00 to $328.00 in a research note on Monday, April 14th. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Leerink Partners started coverage on shares of Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Mizuho dropped their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Finally, William Blair reaffirmed a "market perform" rating on shares of Medpace in a research note on Tuesday, April 22nd.

Insider Buying and Selling at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director owned 2,998 shares in the company, valued at $904,856.36. This trade represents a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 20.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Medpace

Several large investors have recently modified their holdings of MEDP. Jones Financial Companies Lllp increased its stake in shares of Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after purchasing an additional 110 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Medpace in the fourth quarter worth about $31,000. Charles Schwab Investment Management Inc. increased its stake in shares of Medpace by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 201,046 shares of the company's stock worth $66,794,000 after purchasing an additional 2,142 shares in the last quarter. Assetmark Inc. increased its stake in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after purchasing an additional 29 shares in the last quarter. Finally, Proficio Capital Partners LLC increased its stake in shares of Medpace by 4.1% in the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after purchasing an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Price Performance

Shares of Medpace stock traded down $1.24 during trading on Friday, reaching $320.26. 20,837 shares of the company traded hands, compared to its average volume of 373,529. The firm has a market capitalization of $9.20 billion, a PE ratio of 24.50, a P/E/G ratio of 5.80 and a beta of 1.47. Medpace has a 1-year low of $250.05 and a 1-year high of $459.77. The company has a 50 day moving average price of $303.74 and a 200-day moving average price of $319.15.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a net margin of 19.31% and a return on equity of 54.36%. The company had revenue of $558.57 million for the quarter, compared to analysts' expectations of $528.38 million. During the same quarter in the prior year, the firm earned $3.20 EPS. Equities research analysts expect that Medpace will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.